Theratechnologies (THTX) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Theratechnologies Analyst Ratings
BenzingaOct 11 14:45 ET · Ratings
Earnings Call: Theratechnologies Reports Q3 Profit, Raises EBITDA Guidance
InvestingOct 11 12:58 ET
JonesTrading Downgrades Theratechnologies(THTX.US) to Hold Rating
Moomoo NewsOct 10 16:31 ET · Ratings
Theratechnologies (THTX) Was Downgraded to a Hold Rating at JonesTrading
TipRanksOct 10 16:16 ET · Ratings
Theratechnologies Downgraded to Hold From Buy at JonesResearch
TipRanksOct 10 16:15 ET · Ratings
Theratechnologies Inc. (THTX) Q3 2024 Earnings Call Transcript Summary
moomoo AIOct 10 11:04 ET · Conference Call

Comments

Jaguar8

Oct 10 06:31

NEWS

$Theratechnologies (THTX.US)$
Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
• Q3 revenue of $22.6 million represents +8% growth year-over-year
• Positive net income of $3.1 million or 6 cents per share, and Adjusted EBITDA1 of $7.2 million
• Fiscal 2024 guidance revised to between $83 and $85 million in revenue and Adjusted EBITDA guidance increased to a range of $17 to $19 million

Jaguar8

May 23 16:02

$Theratechnologies (THTX.US)$
NEWS
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Theratechnologies announced promising Phase 1 data for its investigational drug, sudocetaxel zendusortide, at the 2024 ASCO annual meeting.
The drug showed long-term disease stabilization in patients with solid tumors, lasting up to 45 weeks even after treatment ceased.
The study highlighted a uni...

1

Jaguar8

May 2 06:31

$Theratechnologies (THTX.US)$
NEWS
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
05/02/2024 - 04:30 AM
First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors
Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing
MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the...

Trytosaveabit

Mar 21 07:35

Update

$Theratechnologies (THTX.US)$ NASDAQ: THTX) announced moving to the next dose level in Part 3 of its Phase 1 clinical trial of sudocetaxel zendusortide in patients with advanced ovarian cancer.

1

Meltyy

Jan 30 03:28

PDUFA Update…

📌Last week’s PDUFAs:
$Heron Therapeutics (HRTX.US)$ : Approved 1/23 🎉
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia (LQDA.US)$ : NDA review ongoing 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
$Theratechnologies (THTX.US)$ : CRL 1/24 🙁
⇒ F8 Formulation of Tesamorelin
⇒ Excess abdominal fat in adults w/ HIV
⇒ sBLA
⇒ PDUFA: 01/22/24
$Sanofi (SNY.US)$ & $Regeneron Pharmaceuticals (REGN.US)$ : Approved 1/25 🎉
⇒ Dupixent
⇒ Eosinophilic esophagitis (pedia)
⇒ sB...

12

1

THTX Theratechnologies

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target